World, Health, Europe, Latest on coronavirus outbreak

UK urges EU to use Oxford COVID-19 vaccine for elderly

New data reveal single dose of Oxford/AstraZeneca vaccine offers high protection

Muhammad Mussa   | 03.03.2021
UK urges EU to use Oxford COVID-19 vaccine for elderly


The UK has urged the EU to start vaccinating its elderly population with the Oxford-AstraZeneca vaccine after a study showed a single dose provides strong protection against the coronavirus.

The Joint Committee on Vaccination and Immunization urged the bloc to “get on” with vaccinating its elderly after the study by the University of Bristol showed a single dose of either the Oxford or the Pfizer vaccine is highly effective at protecting the elderly.

“In the short term, the job’s done in the UK. But there are lots of doses of AstraZeneca vaccine available in European countries, and they are not being given to people over the age of 65, in some cases in countries over the age of 55, for lack of data,” said Professor Adam Finn from the University of Bristol.

“Well, here are the data. There are data from Public Health England and Scotland and now from us showing that you can save lives in elderly people by giving them a dose of the AstraZeneca vaccine. And those countries need to get on and start doing that as fast as possible,” Finn added.

The European Medicines Agency approved the Oxford vaccine for all age groups in January. But the rollout was abruptly halted after states such as Germany, France and Italy recommended against its use for the elderly because of a lack of data.

The findings on Wednesday follow the release of a separate study on Monday by government agency Public Health England that showed the Oxford and Pfizer vaccines offered strong protection for those older than 65 and reduce the risk of serious illness caused by the virus by 80%.

On Wednesday, 6,385 people tested positive for the virus, taking this week’s total to 50,208. This represents a 31.6% decrease in comparison to the last seven days.

Some 315 deaths were reported within 28 days of testing positive for the virus on Wednesday. Between Feb. 25 and March 3, there were 1,864 deaths within 28 days of testing. This shows a 33.8% decrease in comparison to the previous week.

A total of 20,703,615 people had been administered their first dose of the vaccine by the end of March 2, with 895,412 receiving a second dose. Vaccines are currently administered in two doses 21 days apart.

The latest R range for the UK stands at 0.6-0.9, with the current growth rate at -6% to -3% per day. The R number is a mechanism used to rate the virus’s ability to spread, with R being the number of people that one infected person will pass the virus on to.

Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
Related topics
Bu haberi paylaşın